MAHA Commission Report on Children’s Health Takes Aim at Ultra-Processed Foods and Medication Practices, Among Other Targets

May 23, 2025

Reading Time : 2 min

Yesterday, the White House’s Make America Healthy Again (MAHA) Commission, led by the Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. released its inaugural health report titled, Make Our Children Healthy Again, delivering one of the first widely anticipated deliverables from the MAHA Commission Executive Order issued earlier this year and noted in our prior alert. The 72-page assessment examines the rising rates of childhood chronic disease in the country—including obesity, heart disease and diabetes—and explores potential contributing factors. Specifically, the report identifies and focuses on four potential drivers:

  • Ultra-Processed Foods (UPFs). The report links the increased consumption of UPFs high in added sugars, chemical additives and saturated fats to poor health outcomes in children. The report also states that government programs such as the Supplemental Nutrition Assistance Program (SNAP) and the School Breakfast Program and National School Lunch Program (NSLP) have contributed to the overconsumption of UPFs.
  • Exposure to Environmental Chemicals. The Commission identifies a need for continued studies to better understand the impact of exposure to various substances including per- and polyfluoroalkyl substances (PFAS), fluoride, electromagnetic radiation and phthalates.
  • Lack of Physical Activity and Chronic Stress: The report discusses the pervasive use of screens, increasing sedentary lifestyles and childhood mental health decline as areas of concern.
  • Overmedicalization: The report states that “excessive medical intervention” including an overuse of prescription drugs and vaccines may exacerbate chronic childhood illness. The report calls for inquiry into the impacts of vaccine injury, links between vaccines and chronic disease, and conflicts of interest in the development of the vaccine schedule.

Next Steps

The report outlines ten proposed research initiatives, setting the stage for follow-on actions and potential policy changes as the MAHA Commission’s work moves forward. The report identifies ten areas for further research, including recommending several research initiatives to guide efforts to combat childhood chronic disease including evaluating self-affirmed GRAS (Generally Recognized as Safe) food ingredients, assessing the impact of whole-food, reduced-carb and low-UPF diets in children, and applying AI and machine learning to federal health and nutrition datasets for early detection of harmful exposures and childhood chronic disease trends. The report also proposes focusing on research replication, post-marketing surveillance, leveraging real world data to study childhood chronic diseases, drug safety studies, alternative testing models, and mapping gene–environment interactions affecting childhood disease risk. The MAHA Commission plans to release a strategy in August 2025. However, it is likely that the Commission will provide updates on some of these research items before August, and agencies such as FDA and NIH will likely start announcing initiatives based on this report.

Share This Insight

Previous Entries

Eye on FDA

February 17, 2026

On February 3, 2026, the Consolidated Appropriations Act, 2026 (P.L. 119-75) became law and marked an important milestone in the bipartisan congressional effort to reauthorize the rare pediatric disease priority review voucher program. Section 6604 of this law extends the Food and Drug Administration’s (FDA) authority to issue priority review vouchers to encourage treatments for rare pediatric diseases through September 30, 2029.

...

Read More

Eye on FDA

February 17, 2026

In case you missed it, Department of Health and Human Services Secretary Robert F. Kennedy Jr. and former Food and Drug Administration (FDA) Commissioner David Kessler appeared on 60 Minutes this past Saturday, February 15, in a segment titled “Generally Recognized as Safe.” As the title suggests, the conversation centered on FDA’s Generally Recognized as Safe (GRAS) regulatory pathway (for background, see our prior post discussing in more detail the GRAS process), as well as Commissioner Kessler’s August 2025 citizen petition urging FDA to revoke the GRAS status of refined carbohydrates used in industrial food processing (discussed in more detail in our earlier coverage of the petition).

...

Read More

Eye on FDA

February 3, 2026

On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program. The goal of the program is to strengthen the domestic pharmaceutical supply chain by making the review and inspection process more predictable for U.S.-based drug manufacturing facilities.

...

Read More

Eye on FDA

January 28, 2026

The Food and Drug Administration (FDA) has begun 2026 with a clear signal to the direct‑to‑consumer testing industry: self‑collection devices remain firmly within the agency’s regulatory reach, notwithstanding the 2025 court ruling on laboratory developed tests (LDTs). Last week, the agency published warning letters previously issued to four companies—Genetrace, Genovate, Germaphobix and ProDx Health—selling human immunodeficiency virus (HIV) tests that rely on unauthorized self‑collection kits.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.